Protection was achieved in patients seven days after the second of the two doses, and 28 days after the first, according to preliminary results.
Pfizer and BioNTech announced that a vaccine they jointly developed with BioNTech was 90% effective in preventing Covid-19 infections in their phase III ongoing trials.
Protection was achieved in patients seven days after the second of the two doses, and 28 days after the first, according to preliminary results.
"The first set of results from the Covid-19 Phase III vaccine trial provides preliminary evidence of the ability of our vaccine to prevent Covid-19," Albert Burla, Chairman and CEO of Pfizer, said in a statement.
“We are approaching an important step in providing people around the world with a much-needed breakthrough to help end this global health crisis.
"We are reaching this important milestone in our vaccine development program at a time when the world desperately needs it," added Mr. Burla.
Around the world, Covid-19 infection rates are rising to record levels, with hospital intensive care units being filled and the death toll rising as well.
0 Comments